May 17, 2020

Angiotech gets US nod to sell bio-seal lung biopsy tract plug system in U.S.

proprietary Bio-Seal Lung Biopsy Tract Plug System
lung bio
Admin
2 min
Angiotech gets US nod  to sell bio-seal lung biopsy tract plug system
Angiotech Pharmaceuticals,Inc. ("Angiotech") announced today that it received approval from the U.S. Food and Drug Administration ("FDA...

Angiotech Pharmaceuticals, Inc. ("Angiotech") announced today that it received approval  from the U.S. Food and Drug Administration ("FDA") to market and sell its proprietary Bio-Seal Lung Biopsy Tract Plug System in the United States.

The device is the first of its kind approved by the FDA, and represents a significant advance in the safety of this important diagnostic procedure.

"Bio-Seal represents a significant and proprietary addition to our broad portfolio of products for the diagnosis of cancer," said Thomas Bailey, President and CEO of Angiotech. " Mr. Bailey also said, "This device has been shown in clinical studies to significantly reduce complication rates in patients receiving a lung biopsy procedure, which we expect will enable physicians to more aggressively pursue diagnostic options for this patient population."

Angiotech's Bio-Seal product is a novel biopsy device system that contains a proprietary hydrogel plug designed to prevent air leaks that can lead to a collapsed lung, or pneumothorax, in patients having lung biopsies. On contact with moist tissue, the hydrogel plug absorbs fluids and expands to fill the void created by the biopsy needle puncture. The plug is absorbed into the body after healing of the puncture site has occurred.

Pneumothorax is the most common potential complication in patients undergoing lung biopsy procedures. In cases where a chest tube is inserted to treat pneumothorax, an extended hospital stay for such patients may be required until the condition has stabilized. Industry estimates indicate that over 250,000 lung biopsy procedures are performed annually in the United States.

Bio-Seal has undergone a human clinical trial in the United States which was designed to assess the safety and efficacy of Bio-Seal, with the primary endpoint being reduction in rates of pneumothorax in patients undergoing lung biopsy procedures.

The clinical trial was a prospective, randomized, multi-centered safety and efficacy evaluation. The complete data for the Bio-Seal study was presented at the 2009 Society of Interventional Radiology.

The trial achieved its primary end point, with clinical success in 85% of patients treated with Bio-Seal, as compared to 69% for the control patients (p=0.002), representing a 50% reduction in the risk of pneumothorax in the Bio-Seal patient group.

Angiotech expects that this product will be made commercially available in the U.S. during the first quarter of 2013. Angiotech expects market this product globally under the brand name "BioSentry™".

Angiotech is a British Columbia pharmaceutical company that discovers, develops and markets innovative technologies and medical products for local diseases or for complications related with medical device implants, surgical interventions and acute injury. 

Share article

Mar 30, 2021

LG launches purpose-built smart TV for hospitals

smart tv
hospital
video call
Leila Hawkins
2 min
LG launches purpose-built smart TV for hospitals
LG's new smart TVs have been designed to safely improve the patient experience...

LG Business Solutions USA has announced two new hospital TVs that are designed to improve patient management and engagement while adhering to critical safety standards for healthcare facilities.

One of the TVs is LG's biggest ever screen for a hospital - the 65-inch 4K Ultra HD model. It has LG’s NanoCell display technology, enabling it to display vivid pictures, and provides built-in support for hospital pillow speakers and embedded broadband LAN capability, so hospitals can deliver video on demand without requiring a separate set-top box in the patient room.

 It also includes configuration software with an intuitive interface for setting up the TV to work in a hospital setting, plus a software-enabled access point feature that turns the TV into a Wi-Fi hotspot. 

The second TV screen is the 15-inch Personal Healthcare Smart Touch TV with a multi-touch screen. It is designed to be installed on an adjustable arm for use in shared spaces or smaller patient rooms and will support LG's new, modular LG AM-AC21EA video camera, and HD video communication.

Both include support for video conferencing, and are UL Certified for use in healthcare facilities, a global safety standard. They also feature LG’s integrated Pro:Centric hospital management solutions, allowing hospitals and LG’s patient engagement development partners to personalise a patient's room, providing entertainment, hospital information, services, patient education, and more. 

Additionally its communication platform makes it possible to conduct video calls between patients and clinicians or family.

“Our newest LG hospital TVs reflect ongoing feedback from the industry and include capabilities integrated to meet the unique needs of a critical market” said Tom Mottlau, Director of Healthcare Solutions, LG Electronics USA.

“Our healthcare patient engagement development partners requested an upgradable version of webOS for our Pro:Centric smart TV platform so they could more easily introduce new features for their hospital customers. For the latest versions of webOS, LG worked closely with our partners to make their request a reality and to deliver a hospital TV platform that can evolve over time.”

Share article